Epithalon (Epitalon), the synthetic pineal tetrapeptide Ala-Glu-Asp-Gly, is supplied exclusively as an unregistered research chemical for in-vitro and preclinical use. The Body Pharm Epithalon 20 pre-filled pen is one format referenced by researchers in 2026. It is an investigational research compound with no approved human therapeutic indication.
For researchers evaluating Epithalon, two practical factors matter: HPLC (High-Performance Liquid Chromatography) purity (typically ≥99% on research-grade listings) and batch-specific Certificate of Analysis (CoA) availability on request.
This guide covers what Epithalon is at the molecular level, what the research evidence actually shows about telomerase activation and circadian effects, and what handling and research considerations apply.
Last updated: 2026
Key Takeaways
- Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) supplied as an unregistered research chemical with no approval for human use
- The evidence base is preclinical: in-vitro telomerase activation and rodent circadian-rhythm data exist, but no Phase III human trials have been published as of 2026
- The Body Pharm Epithalon 20 pen is a ready-to-use liquid format requiring 2–8 °C storage and batch-specific CoA verification before use
- Liquid peptide formats require cold-chain handling to avoid degradation from freeze-thaw and temperature excursions
- Regulatory status differs between countries; it is an investigational compound supplied for laboratory research use only
What Is Epithalon? Sequence, Origin, and Structure
Epithalon is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (AEDG), a molecular weight of 390.35 g/mol, and CAS number 307297-39-8. It is the synthetic analogue of epithalamin, a polypeptide complex originally extracted from the bovine pineal gland. In the Russian gerontology literature, researchers classify it as a short peptide bioregulator rather than a hormone.
The IUPAC designation is L-alanyl-L-glutamyl-L-aspartyl-glycine. At 390 Da, AEDG sits at the small end of the bioactive peptide range. Its low molecular weight is cited in pre-2020 literature as the basis for proposed direct interaction with promoter regions of genes including the TERT locus encoding the catalytic subunit of telomerase.
Khavinson and the St Petersburg origin
Professor Vladimir Khavinson and colleagues at the St Petersburg Institute of Bioregulation and Gerontology isolated and characterised the AEDG sequence synthetically. Their group published the foundational telomerase-activation and melatonin-modulation findings that subsequent review work has reproduced. They frame Epithalon as a peptide bioregulator: an endogenous-analogue signalling molecule that modulates gene expression at sub-hormonal concentrations. This differs from classical endocrine hormones, which operate through receptor-mediated dose-response curves.
Synthetic vs natural source
The Epithalon supplied for research in 2026, including the Body Pharm Epithalon 20 pen format, is solid-phase synthesised AEDG rather than a pineal extract. This distinction matters for purity work: synthetic AEDG is characterised by HPLC against a defined reference, whereas the historical epithalamin complex was a heterogeneous peptide mixture. Researchers benchmarking Epithalon alongside other pen-format research peptides such as Body Pharm CJC-1295 & Ipamorelin 20, or pairing it with NAD+ in cellular-ageing protocols, should request the batch CoA to confirm sequence identity and ≥98% HPLC purity before use.
Telomerase Activation: What the Research Shows
Epithalon upregulates TERT transcription and restores telomerase activity in somatic cell lines that normally lack it. The evidence base remains preclinical: as of 2026, no Phase III human randomised controlled trials on telomerase or telomere endpoints have been published. Researchers procuring AEDG should weight the mechanistic literature accordingly and avoid translating in-vitro passage data into human longevity claims.
The absence of human trials does not undermine the compound's research value. The preclinical signal is sufficiently reproducible to justify mechanistic studies in cell culture and animal models; the gap is simply that no controlled human trial has been funded or completed.
The hTERT upregulation mechanism
The proposed mechanism is direct. AEDG's small size and charge profile are cited as the basis for binding promoter regions of the TERT gene, derepressing transcription of the telomerase catalytic subunit. Reactivated telomerase then adds TTAGGG repeats to chromosome ends, extending replicative capacity in cells that had silenced TERT during differentiation. This is a transcriptional-regulator model rather than a receptor-agonist model, which is why dose-response data for Epithalon does not resemble classical pharmacology.
Key in-vitro and animal findings
The Khavinson group's foundational telomerase-activation work in human somatic cell cultures, summarised in subsequent reviews, reported increased telomerase activity and additional population doublings beyond the Hayflick limit in treated fibroblast lines. Animal models cited in the same review literature describe modulation of melatonin synthesis and circadian markers alongside lifespan effects in rodents. Vaiserman and colleagues' 2021-era review of peptide bioregulators and telomere biology continues to cite Epithalon as the prototype short-peptide telomerase modulator, while noting the absence of fresh primary human data.
What telomere elongation data actually shows
The hard numbers describe cell passages, not human lifespan. In-vitro extension of replicative capacity in fibroblast cultures, and rodent median-lifespan shifts, are the endpoints on record. None of this constitutes evidence that Epithalon extends human healthspan or reverses biological age in vivo. No peer-reviewed publication between 2023 and mid-2026 has closed that gap with a controlled human trial.
Honest framing for 2026 research
For a research lab, the defensible position is: Epithalon is a well-characterised tetrapeptide with reproducible in-vitro telomerase-activation signal and supportive rodent data. It is suitable for mechanistic and cellular-ageing studies in models such as senescent fibroblasts, or as a comparator alongside NAD+ precursor work. It is not a validated human therapeutic, and protocols pairing it with growth-axis peptides like the Body Pharm CJC-1295 & Ipamorelin 20 Pen should remain strictly preclinical.
Circadian Regulation and the Pineal Axis
Epithalon's second mechanistic axis is restoration of pineal melatonin output and resynchronisation of circadian markers in aged animal models. This is distinct from but biologically linked to its telomerase signal. The tetrapeptide derives from epithalamin, the original bovine pineal extract characterised by Khavinson's group, and acts on the hypothalamic-pineal axis to upregulate nocturnal melatonin synthesis where age-related decline has flattened the rhythm.
Melatonin and HPA-axis findings on record
In aged rodent and non-human primate work cited across the pineal-peptide review literature, Epithalon administration is associated with normalisation of the nocturnal melatonin peak, restoration of cortisol rhythm amplitude, and shifts in hypothalamic-pituitary-adrenal (HPA) axis reactivity toward a younger phenotype. These are the endpoints chronobiology researchers most often reference when justifying Epithalon as a probe compound. No 2023–2026 human trial has reproduced these findings under controlled conditions, so the data remains animal-model and in-vitro in character.
Where Epithalon sits among pineal peptides
Three short peptides dominate this niche: Epithalamin (the parent polypeptide extract), Epithalon (Ala-Glu-Asp-Gly, the synthetic tetrapeptide active fragment), and Pinealon (Glu-Asp-Arg, a related tripeptide). Pinealon is more often studied for neuroprotective and anti-oxidative endpoints than for telomere biology. Epithalon is the only one of the three with both a reproducible in-vitro telomerase-activation signal and a melatonin-rhythm dataset, which makes it a more versatile research tool than either of the others.
Why the dual mechanism matters for protocol design
For a chronobiology lab, this dual profile permits experimental designs that decouple replicative-senescence endpoints from circadian endpoints within a single compound. Researchers can pair fibroblast passage-limit assays with melatonin ELISA (Enzyme-Linked Immunosorbent Assay) timepoints in parallel cohorts. Researchers building broader cellular-ageing panels often run Epithalon alongside NAD+ precursor arms. Where a growth-axis comparator is needed, the Body Pharm CJC-1295 & Ipamorelin 20 Pen provides a format-matched secretagogue control for preclinical work.
Body Pharm Epithalon 20 Pen, Product Specifications
The Body Pharm Epithalon 20 Pen is a pre-filled, ready-to-use liquid pen format that ships without requiring reconstitution. Body Pharm supplies it in multi-dose pen presentations, mirroring its delivery format for other compounds in the range such as the Body Pharm CJC-1295 & Ipamorelin 20 Pen.
What "20" denotes in the pen designation
The "20" suffix conventionally refers to the total peptide content of the cartridge in milligrams rather than a per-actuation dose. This pattern is inferred from analogous pen-format listings for GLP-1 (Glucagon-Like Peptide-1) and BPC-157 (Body Protection Compound-157) products. The exact micrograms delivered per click is not published on a public Body Pharm technical sheet as of 2026. Researchers planning dose-response work should request the product insert and a batch-specific Certificate of Analysis directly from the supplier before designing assays.
Storage, stability, and CoA scope
Liquid-format peptide pens of this class require refrigerated storage at 2–8 °C and should not be subjected to freeze-thaw cycles, which degrade tetrapeptide integrity and shift HPLC purity downward over time. Liquid-format pens of this class should be moved under insulated cold-chain conditions to preserve tetrapeptide integrity in transit. The Certificate of Analysis, where issued on request, covers identity confirmation, HPLC purity (research-grade Epithalon is commonly specified at ≥99% by HPLC), and residual solvent or endotoxin screening depending on batch.
Pen format versus lyophilised vial workflows
The pen removes the variability introduced by manual reconstitution with bacteriostatic water, which is the dominant source of concentration error in lyophilised vial protocols. That trade-off comes at the cost of flexibility: vial setups allow custom reconstitution volumes for specific in-vitro molarity targets, while the pen fixes the working concentration. Researchers running parallel cellular-ageing panels alongside NAD+ precursor arms tend to prefer the pen for reproducibility across long passage-limit studies.
Regulatory status
Epithalon is an investigational research compound supplied strictly for laboratory research use only. It is not an approved medicine, and its regulatory status differs between countries. Verify the applicable rules in your own jurisdiction before handling.
Epithalon vs Related Pineal Peptides, Quick Comparison
Epithalon is the most-studied synthetic pineal peptide as of 2026, with a defined tetrapeptide sequence (Ala-Glu-Asp-Gly) that distinguishes it from its natural-extract predecessor Epithalamin and from the shorter tripeptide Pinealon. All three sit within the Khavinson short-peptide bioregulator classification developed at the St Petersburg Institute of Bioregulation and Gerontology, which groups tissue-specific peptides by amino acid sequence and target organ.
| Peptide | Sequence | Origin | Primary Research Use | Key Study Era |
|---|---|---|---|---|
| Epithalon (Epitalon) | Ala-Glu-Asp-Gly | Synthetic analogue of Epithalamin | Telomerase activation, circadian/melatonin modulation | Pre-2020 in-vitro and animal work |
| Epithalamin | Polypeptide mixture | Bovine pineal extract | Historical precursor; melatonin rhythm studies | 1980s–1990s Russian literature |
| Pinealon | Ala-Glu-Asp | Synthetic tripeptide | Neuroprotective and cognitive ageing models | Pre-2020 animal studies |
Epithalon's evidence volume exceeds the other two largely because its defined four-residue sequence is easier to synthesise to ≥98% HPLC purity and reproduce across laboratories. Epithalamin's extract-based composition resists standardisation. Pinealon appears in a narrower neurological literature and has not attracted comparable telomerase-focused replication.
Where NAD+ fits
For researchers building a cellular-ageing panel, NAD+ operates on a parallel but mechanistically distinct axis. It provides sirtuin substrate availability and mitochondrial redox support rather than telomere maintenance, making it a complementary rather than overlapping research compound. Laboratories running Epithalon protocols often pair it with NAD+ assays to separate telomere-length endpoints from sirtuin-driven readouts. For growth-axis comparators in the same Body Pharm pen format, the Body Pharm CJC-1295 & Ipamorelin 20 Pen is the standard cross-reference.
Storage, Handling, and Research Protocols
Store the Body Pharm Epithalon 20 pen at 2–8 °C in its original carton, protected from direct light. Keep lyophilised Epithalon powder (if sourced separately) at −20 °C for long-term stability. Ala-Glu-Asp-Gly is a short tetrapeptide whose amide and carboxyl side chains are susceptible to oxidative degradation. Avoid repeated freeze-thaw cycles. Aliquot reconstituted powder into single-use volumes rather than cycling a master vial.
For the pen format, Epitalon pens are ready-to-use liquid preparations that do not require reconstitution. The same handling logic applied to the Body Pharm CJC-1295 & Ipamorelin 20 Pen transfers directly here. Prime the device per the supplier insert before first actuation. Refrigerate between uses and discard once the printed in-use period elapses. For in-vitro work, draw from the cartridge with a 29–31 G insulin needle into sterile buffer. For preclinical rodent models, 27–29 G subcutaneous needles are standard in the published literature.
Dosing ranges in the literature
Pre-2020 rodent studies referenced in mechanistic reviews administered Epithalon at roughly 0.1–1.0 mg/kg in animal protocols. In-vitro telomerase activation was observed at nanomolar to low-micromolar concentrations in human somatic cell cultures. These are research figures, not human dosing guidance.
Record-keeping
Log batch number, CoA reference, receipt date, storage temperature excursions, reconstitution solvent and volume, and actuation count per experiment. Researchers building a cellular-ageing panel alongside NAD+ assays should record both compounds under a single study identifier to keep telomere and sirtuin endpoints traceable.
Frequently Asked Questions
What is the difference between Epithalon and Epitalon?
There is no chemical difference. "Epithalon" and "Epitalon" are interchangeable names for the same synthetic tetrapeptide Ala-Glu-Asp-Gly, originally derived from pineal gland research. Vendors use both spellings: some market "Epitalon" pens, while Body Pharm and others label the identical sequence "Epithalon".
Does Body Pharm Epithalon 20 require reconstitution?
No. Epitalon pens, including the Body Pharm 20 format, are supplied as ready-to-use liquid preparations and do not require reconstitution before first use. The "20" suffix conventionally denotes total peptide content per cartridge rather than per-actuation dose. Researchers should request the supplier insert for the exact µg-per-click figure.
How should I store Epithalon after opening?
Refrigerate the opened pen or reconstituted vial at 2–8 °C and discard once the printed in-use period elapses. Avoid repeated freeze-thaw cycles, since the Glu and Asp side chains are susceptible to oxidative degradation. For powder formats, aliquot reconstituted material into single-use volumes in sterile bacteriostatic water rather than cycling a master vial.
Can I use Epithalon in human subjects?
No. Epithalon is not an approved medicine, holds no EMA (European Medicines Agency) authorisation, and does not appear in the FDA (Food and Drug Administration) Orange Book as of 2026. Supply is restricted to in-vitro assays and preclinical animal models. Researchers running parallel longevity-pathway work, such as NAD+ assays, must maintain the same non-human protocol boundary.
What purity standard should research-grade Epithalon meet?
Research-grade Epithalon should meet ≥98% HPLC purity, with 99%+ being standard among reputable international suppliers publishing third-party lab reports. Always request a batch-specific Certificate of Analysis from the vendor before use. Apply the same CoA discipline used for the Body Pharm CJC-1295 & Ipamorelin 20 Pen.
Next Steps
If you are planning to use Epithalon for a cellular-ageing or chronobiology study, start by confirming your institution's ethics approval pathway for animal or human-derived cell-line work. Request a batch-specific Certificate of Analysis and product insert for the Body Pharm Epithalon 20 pen before use, and maintain full storage and handling records. If you are designing a multi-pathway ageing panel, consider pairing Epithalon with NAD+ assays to separate telomere-length from sirtuin-driven readouts, and use the Body Pharm CJC-1295 & Ipamorelin 20 Pen as a growth-axis comparator if your protocol requires one.
